Thermo Fisher Scientific (NYSE:TMO) Stock Rating Reaffirmed by Robert W. Baird


Share on StockTwits

Thermo Fisher Scientific (NYSE:TMO)‘s stock had its “buy” rating restated by analysts at Robert W. Baird in a research note issued on Monday, Price Targets.com reports.

Several other brokerages have also recently weighed in on TMO. UBS Group dropped their price target on shares of Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a research note on Monday, March 29th. Evercore ISI raised their price objective on shares of Thermo Fisher Scientific from $525.00 to $540.00 and gave the company an “outperform” rating in a research report on Thursday, April 22nd. SVB Leerink raised their price objective on shares of Thermo Fisher Scientific from $525.00 to $560.00 and gave the company an “outperform” rating in a research report on Tuesday, February 2nd. Citigroup raised their price objective on shares of Thermo Fisher Scientific from $500.00 to $530.00 and gave the company a “buy” rating in a research report on Tuesday, February 2nd. Finally, Barclays assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 8th. They set an “overweight” rating and a $525.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $534.45.

Shares of TMO stock opened at $465.28 on Monday. Thermo Fisher Scientific has a 12-month low of $324.35 and a 12-month high of $532.57. The company has a current ratio of 2.93, a quick ratio of 2.31 and a debt-to-equity ratio of 0.66. The firm’s 50 day moving average is $468.42 and its 200 day moving average is $476.02. The stock has a market capitalization of $182.86 billion, a P/E ratio of 38.14, a P/E/G ratio of 1.40 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 29th. The medical research company reported $7.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $6.69 by $0.52. The business had revenue of $9.91 billion for the quarter, compared to analysts’ expectations of $9.69 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The company’s revenue was up 59.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.94 EPS. As a group, equities analysts predict that Thermo Fisher Scientific will post 19.03 earnings per share for the current year.

Several large investors have recently modified their holdings of TMO. Eudaimonia Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 248.1% during the 3rd quarter. Eudaimonia Partners LLC now owns 536 shares of the medical research company’s stock worth $237,000 after purchasing an additional 382 shares during the period. Red Spruce Capital LLC boosted its stake in shares of Thermo Fisher Scientific by 8.6% during the 4th quarter. Red Spruce Capital LLC now owns 993 shares of the medical research company’s stock worth $463,000 after purchasing an additional 79 shares during the period. Private Trust Co. NA boosted its stake in shares of Thermo Fisher Scientific by 1.7% during the 4th quarter. Private Trust Co. NA now owns 7,639 shares of the medical research company’s stock worth $3,558,000 after purchasing an additional 129 shares during the period. Woodstock Corp boosted its stake in shares of Thermo Fisher Scientific by 7.8% during the 4th quarter. Woodstock Corp now owns 17,024 shares of the medical research company’s stock worth $7,929,000 after purchasing an additional 1,233 shares during the period. Finally, Fulton Bank N.A. boosted its stake in shares of Thermo Fisher Scientific by 3.7% during the 4th quarter. Fulton Bank N.A. now owns 4,543 shares of the medical research company’s stock worth $2,116,000 after purchasing an additional 162 shares during the period. 87.17% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Article: What is Cost of Goods Sold (COGS)?

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.